Contrary to the results in aRMS, AP-2β seems to be a favorable prognostic marker in carcinomas such as endometrial cancer (Wu and Zhang 2018), cervical cancer (Wang et al. 2017), renal cell cancer (Oya et al. 2004), neuroblastoma (Ikram et al. 2016; Thorell et al. 2009) and breast cancer (BC) (Raap et al. 2018; Yoldi et al. 2016). This evidence concerns the gene TFAP2B and breast cancer.